IRBM Science Park (Pomezia)

 research, scientific research institute / centre

IRBM is largest independent Partner Research Organization for drug discovery and preclinical development. Established in 1999 as the Italian site of Merck Research Laboratories, IRBM was divested by Merck in 2009, and reopened in 2010 as an independent company, retaining the scientific team responsible for the development of five marketed drugs as of 2017.

The core expertise extends from assay development and high-throughput screening to in vivo preclinical pharmacology assessments. The team consists of over 180 experienced chemists and biologists with extensive industry experience, providing not just the ability to pursue your project, but also the scientific advice and expertise it needs to advance quickly and efficiently from a validated target to a strong drug candidate.

Many of our drug hunters have been working at IRBM since before our restructuring into a private company. In fact, in addition to several preclinical candidates currently in clinical trials, they have been responsible for developing or co-developing five marketed drugs thus far, starting with ZOLINZA® in 2006, followed by ISENTRESS® in 2008, NERVENTRA® in 2013, Grazoprevir (one of two active ingredients in ZAPATIER®) in 2016 and ZEJULA® in 2017.